SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549


                                    FORM 10-Q


Mark One:
[X]            QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                       For the quarter ended June 30, 1999

                                       OR

[ ]           TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


                         Commission File Number 0-27324


                       SYNAPTIC PHARMACEUTICAL CORPORATION
             (Exact name of registrant as specified in its charter)


          Delaware                                 22-2859704
(State or other jurisdiction            (I.R.S. Employer Identification No.)
of incorporation or organization)


          215 College Road
            Paramus, NJ                               07652
(Address of principal executive offices)            (Zip Code)

                                 (201) 261-1331
              (Registrant's telephone number, including area code)



Indicate  by check  mark  whether  the  registrant:  (1) has filed  all  reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days.

                                    Yes X No


As of August 1, 1999, there were 10,743,161  shares of the  registrant's  Common
Stock outstanding.


<PAGE>



                       SYNAPTIC PHARMACEUTICAL CORPORATION

   INDEX TO QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 1999


                          PART I. FINANCIAL INFORMATION

                                                                         Page
                                                                         ----
Item 1. Financial Statements                                               1

Balance Sheets at June 30, 1999 and December 31, 1998                      1

Statements of Operations and Comprehensive Income (Loss) for
  the three months ended June 30, 1999 and 1998, and for the
  six months ended June 30, 1999 and 1998                                  2

Statements of Cash Flows for the six months ended
 June 30, 1999 and 1998                                                    3

Note to Financial Statements                                               4

Item 2. Management's Discussion and Analysis of Financial
  Condition and Results of Operations                                      5

Item 3. Quantitative and Qualitative Disclosures About Market Risk        10



                           PART II. OTHER INFORMATION


Item 4. Submission of Matters to a Vote of Security Holders               11

Item 6. Exhibits and Reports on Form 8-K                                  12

Signatures                                                                13



























                                       (i)


<PAGE>



                          PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

                       SYNAPTIC PHARMACEUTICAL CORPORATION
                                 BALANCE SHEETS
                    (in thousands, except share information)

                                     ASSETS

                                                        June 30,  December 31,
                                                          1999        1998
                                                      ----------  -----------
                                                      (Unaudited)   (Audited)
Current assets:
 Cash and cash equivalents                               $ 9,307      $16,590
 Restricted cash                                              --          600
 Marketable securities--current maturities                 6,884        7,133
 Other current assets                                      1,076        1,064
                                                          -------      -------
  Total current assets                                    17,267       25,387

Property and equipment, net                                5,758        5,733

Marketable securities                                     32,887       32,655

Patent and patent application costs,
  net of accumulated amortization                            752          921
                                                         -------      -------
                                                         $56,664      $64,696
                                                         =======      =======

                      LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
 Accounts payable                                        $   698      $   966
 Accrued liabilities                                         379          645
 Accrued compensation                                        210          326
 Unearned revenue under research agreement                   279           83
                                                         -------      -------
  Total current liabilities                                1,566        2,020

Deferred rent obligation                                      82           --

Stockholders' equity:
 Preferred Stock, $.01 par value; authorized--
  1,000,000 shares; issued--none                              --           --
 Common Stock, $.01 par value; authorized--
  25,000,000 shares; issued and outstanding--
  10,743,161 shares in 1999 and 10,711,374 shares
  in 1998;                                                   107          107
 Additional paid-in capital                               98,689       98,516
 Accumulated other comprehensive income--
  net unrealized  losses on securities                      (562)         (77)
 Deferred compensation                                       (30)         (61)
 Accumulated deficit                                     (43,188)     (35,809)
                                                         -------      -------
  Total stockholders' equity                              55,016       62,676
                                                         -------      -------
                                                         $56,664      $64,696
                                                         =======      =======

                        See note to financial statements.

                                        1


<PAGE>



                       SYNAPTIC PHARMACEUTICAL CORPORATION
            STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
             (in thousands, except share and per share information)
                                   (Unaudited)



                             For the three months       For the six months
                                ended June 30,            ended June 30,
                               1999         1998         1999         1998
                             -------      -------      -------      -------
Revenues:
 Contract revenue            $   843      $ 2,148      $ 1,487      $ 4,313
 License revenue                  --           --           --        2,000
 Grant revenue                    --           60           --          150
                             -------      -------      -------      -------
  Total revenues                 843        2,208        1,487        6,463

Expenses:
 Research and development      3,814        3,851        7,800        7,512
 General and administrative    1,292        1,085        2,498        2,168
                             -------      -------      -------      -------
  Total expenses               5,106        4,936       10,298        9,680
                             -------      -------      -------      -------
Loss from operations          (4,263)      (2,728)      (8,811)      (3,217)

Other income, net:
 Interest income                 695          953        1,430        1,871
 Gain on sale of securities       --           --            2           --
                             -------      -------      -------      -------
  Other income, net              695          953        1,432        1,871
                             -------      -------      -------      -------
Net loss                     $(3,568)     $(1,775)     $(7,379)     $(1,346)
                             =======      =======      =======      =======


Comprehensive loss:

Net loss                     $(3,568)     $(1,775)     $(7,379)     $(1,346)

Unrealized losses (gains)
 arising during period          (355)         121         (473)          24

Less: Reclassification
 adjustment for gains
 included in net income           --           --          (12)          --
                             -------      -------      -------      -------
Comprehensive loss           $(3,923)     $(1,654)     $(7,864)     $(1,322)
                             =======      =======      =======      =======


Basic and diluted net loss
 per share                    $(0.33)      $(0.17)      $(0.69)      $(0.13)
                              ======       ======       ======       ======
Shares used in
 computation of basic
 and diluted net loss
 per share                10,742,618   10,691,744   10,735,167   10,668,641
                          ==========    =========   ==========    =========



                        See note to financial statements.

                                        2


<PAGE>



                       SYNAPTIC PHARMACEUTICAL CORPORATION
                            STATEMENTS OF CASH FLOWS
                                 (in thousands)
                                   (Unaudited)
                                                        For the six months
                                                          ended June 30,
                                                        1999          1998
                                                       -------      -------
Operating activities:

Net loss                                               $(7,379)     $(1,346)
Adjustments to reconcile net loss to net
 cash used in operating activities:
Deferred rent obligation                                    82           --
Depreciation and amortization                              798          702
Amortization of premiums/(discounts) on securities         227           74
Amortization of deferred compensation                       31           41
Gain on sale of securities                                  (2)          --
Changes in operating assets and liabilities:
Decrease (increase) in other current assets                588         (484)
Decrease in accounts payable, accrued liabilities
  and accrued compensation                                (650)        (291)
Increase in collaborative agreement
  revenue receivable                                        --         (120)
Increase in deferred revenue                               196          313
                                                       -------      -------
Net cash used in operating activities                   (6,109)      (1,111)


Investing activities:

Sale or maturity of investments                         15,656       30,000
Purchase of investments                                (16,349)     (39,120)
Purchases of property and equipment                       (654)        (808)
                                                       -------      -------
Net cash used in investing activities                   (1,347)      (9,928)


Financing activities:

Issuance of common stock, net of repurchases               173        1,374
                                                       -------      -------
Net cash provided by financing activities                  173        1,374
                                                       -------      -------

Net decrease in cash and cash equivalents               (7,283)      (9,665)


Cash and cash equivalents at beginning of period        16,590       23,113
                                                       -------      -------

Cash and cash equivalents at end of period             $ 9,307      $13,448
                                                       =======      =======









                        See note to financial statements.

                                        3


<PAGE>



                       SYNAPTIC PHARMACEUTICAL CORPORATION
                          NOTE TO FINANCIAL STATEMENTS
                                  June 30, 1999


Note 1 -- Basis of Presentation

         The accompanying  unaudited financial  statements have been prepared in
accordance  with  the  instructions  to  Form  10-Q  and  may  not  include  all
information  and  footnotes  required  for a  presentation  in  accordance  with
generally accepted  accounting  principles.  In the opinion of the management of
Synaptic Pharmaceutical Corporation (the "Company"),  these financial statements
include all normal and recurring  adjustments  necessary for a fair presentation
of the financial  position and the results of  operations  and cash flows of the
Company  for  the  interim  periods  presented.   For  more  complete  financial
information,  these financial  statements should be read in conjunction with the
audited  financial  statements  for the fiscal year ended December 31, 1998, and
notes  thereto  included in the Company's  1998 Annual Report on Form 10-K.  The
results of  operations  for the fiscal  quarter  ended  June 30,  1999,  are not
necessarily  indicative of the results of operations to be expected for the full
year.












































                                        4


<PAGE>



Item 2.     Management's Discussion and Analysis of Financial Condition and
               Results of Operations

Overview

         Synaptic Pharmaceutical  Corporation is a biotechnology company engaged
in the  development  of a broad platform of enabling  technology  which it calls
"human  receptor-targeted drug design technology." The Company is utilizing this
technology to discover and clone the genes that code for human receptor subtypes
that  may  be  associated   with  specific   disorders.   The  Company  and  its
collaborative  partner  and other  licensees  are in turn  utilizing  the cloned
receptor genes to design  compounds  that can  potentially be developed as drugs
for treating these disorders.

         The  Company  is   currently   collaborating   with   Grunenthal   GmbH
("Grunenthal").  Concurrently  with  the  establishment  of  this  collaborative
arrangement,  the  Company  granted a license to certain of its  technology  and
patent rights to Grunenthal.

         In  addition  to its  ongoing  collaborative  arrangement,  four  other
pharmaceutical  companies,  Eli Lilly and Company  ("Lilly"),  Merck & Co., Inc.
("Merck"),  Novartis Pharma AG ("Novartis"),  and Glaxo Group Limited ("Glaxo"),
have  licenses to certain of the Company's  technology  and patent  rights.  The
Lilly,   Merck  and  Novartis  licenses  were  granted   concurrently  with  the
establishment of collaborative arrangements with such companies. While the Lilly
collaboration,  the Merck collaboration and the Novartis  collaboration ended in
July 1999, February 1999 and August 1998, respectively,  the associated licenses
continue  for  the  respective   periods  provided  in  these  agreements.   For
convenience of reference, the agreements pursuant to which the licenses referred
to in this paragraph and the preceding  paragraph were granted are  collectively
referred to as the "License Agreements."

         Since  inception,  the Company has  financed its  operations  primarily
through  the sale of its stock,  through  contract  and  license  revenue  under
certain of its License Agreements, and through interest income and capital gains
resulting  from its  investments.  The Company also has received  revenues  from
government grants under the Small Business  Innovative Research ("SBIR") program
of the National Institutes of Health.

         To  date,  the  Company's  expenditures  have  been  for  research  and
development related expenses, general and administrative related expenses, fixed
asset purchases and various patent related  expenditures  incurred in protecting
the Company's technologies.  The Company has been historically  unprofitable and
had an accumulated  deficit of $43,188,000 at June 30, 1999. The Company expects
to continue to incur  operating  losses for a number of years and may not become
profitable,  if at all, unless and until it receives  royalty revenue or revenue
from sales of drugs that may be developed  with the use of its technology or its
patent rights.

Results of Operations

Comparison of the Three Months Ended June 30, 1999 and 1998

         Revenues. The Company recognized revenue of $843,000 and $2,208,000 for
the three  months  ended June 30, 1999 and 1998,  respectively.  The decrease of
$1,365,000 was  attributable  primarily to a net decrease in contract revenue of
$1,305,000  resulting from the  contractual  termination of two of the Company's
collaborative  arrangements and the reduction in full-time equivalent scientists
being funded under another of the Company's collaborative arrangements.

         Research and Development  Expenses.  The Company incurred  research and
development  expenses of  $3,814,000,  and $3,851,000 for the three months ended
June 30,  1999 and  1998,  respectively.  The  decrease  of  $37,000,  or 1%, in
research and development  expenses was attributable  primarily to: reductions in
recruiting  fees and expenses as well as reductions in salary costs due to a net
decrease in

                                        5


<PAGE>



headcount, both of which were offset by: increased rent expense for facilities
resulting from previously contracted increases in square footage; and increased
supply costs.

         General and Administrative  Expenses.  The Company incurred general and
administrative  expenses of $1,292,000 and $1,085,000 for the three months ended
June 30, 1999 and 1998,  respectively.  The  increase of  $207,000,  or 19%, was
attributable  primarily to an increase in rent expense resulting from previously
contracted increases in square footage.

         Other Income,  Net. The Company  recorded  other income of $695,000 and
$953,000 for the three months  ended June 30, 1999 and 1998,  respectively.  The
decrease of $258,000 was primarily due to lower  average cash,  cash  equivalent
and marketable securities balances during the second quarter of 1999 as compared
with the same period in the prior year.

         Net Loss and  Basic  and  Diluted  Net  Loss  Per  Share.  The net loss
incurred by the Company was $3,568,000 ($0.33 per share),  and $1,775,000 ($0.17
per share) for the three months ended June 30, 1999 and 1998, respectively.  The
increase in net loss per share of $0.16  resulted  primarily from lower revenues
and other  income and  higher  expenses  during  the  second  quarter of 1999 as
described above.

Comparison of the Six Months Ended June 30, 1999 and 1998

         Revenues.  The Company  recognized revenue of $1,487,000 and $6,463,000
for the six months ended June 30, 1999 and 1998,  respectively.  The decrease of
$4,976,000 was attributable  primarily to the following:  the receipt in 1998 of
$2,000,000 of non-recurring  license revenue; and a decrease in contract revenue
of $2,826,000 resulting from the contractual termination of two of the Company's
collaborative  arrangements and the reduction in full-time equivalent scientists
being funded under another of the Company's collaborative arrangements.

         Research and Development  Expenses.  The Company incurred  research and
development expenses of $7,800,000, and $7,512,000 for the six months ended June
30, 1999 and 1998,  respectively.  The increase of $288,000,  or 4%, in research
and  development  expenses was  attributable  primarily  to: an increase in rent
expense  resulting from previously  contracted  increases in square footage,  an
increase in facility related costs and increased supply costs, all of which were
offset by decreases in travel related  expenditures and reductions in recruiting
fees and expenses.

         General and Administrative  Expenses.  The Company incurred general and
administrative  expenses of $2,498,000  and  $2,168,000 for the six months ended
June 30, 1999 and 1998,  respectively.  The  increase of  $330,000,  or 15%, was
attributable  primarily to increases in: rent expense  resulting from previously
contracted increases in square footage; and compensation expenses.

         Other Income,  Net. The Company recorded other income of $1,432,000 and
$1,871,000  for the six months ended June 30, 1999 and 1998,  respectively.  The
decrease of  $439,000  was  primarily  due to lower cash,  cash  equivalent  and
marketable  securities  balances  during 1999 as a result of the  utilization of
these resources to fund the Company's operations.

         Net Loss and  Basic  and  Diluted  Net  Loss  Per  Share.  The net loss
incurred by the Company was $7,379,000 ($0.69 per share),  and $1,346,000 ($0.13
per share) for the six months  ended June 30, 1999 and 1998,  respectively.  The
increase in net loss per share of $0.56  resulted  primarily from lower revenues
and other income and higher  expenses during the first half of 1999 as described
above.

Operating Trends

         Revenues may vary from period to period  depending on numerous  factors
including the timing of revenue earned under the License Agreements and revenue

                                        6


<PAGE>



that may be earned under future collaborative and/or license agreements.  During
the three  months ended June 30, 1999,  the Company  recognized  an aggregate of
$843,000  in revenue.  The  Company  currently  expects  revenue to  approximate
$1,800,000 in 1999.  Furthermore,  under the terms of one or more of the License
Agreements,  additional  revenues may be  recognized if certain  milestones  are
achieved.   Management   continues  to  assess  the  opportunity  for  obtaining
additional funding under new collaborative  and/or license agreements as well as
obtaining  financing  through  equity  transactions.  The Company  continues  to
monitor  its  spending  level in order to insure that it has enough cash to last
through the year 2001.

         Other  income,  net is expected to decline in 1999 and 2000 as existing
funds are utilized to support the Company's operations.

         Property and  equipment  spending in 1999 is expected to decrease  from
that of  1998 as the  Company  completes  the  conversion  of a  portion  of its
underutilized space into laboratory space.

         At June 30,  1999,  the  Company  held  marketable  securities  with an
estimated  fair  value of  $39,771,000.  The  Company's  primary  interest  rate
exposure results from changes in short-term interest rates. The Company does not
purchase financial instruments for trading or speculative  purposes.  All of the
marketable  securities held by the Company are classified as  available-for-sale
securities. The following table provides information about marketable securities
held by the Company at June 30, 1999:
                                                                       Estimated
       Principal Amount and Weighted Average Stated Rate                Fair
                   by Expected Maturity                                Value
-------------------------------------------------------------        ---------
(000's)      1999    2000    2001     2002     2003    Total          (000's)
-------------------------------------------------------------        ---------
Principal   $3,383  $6,487  $20,440  $2,500   $6,500  $39,310         $39,771

Weighted
 Average
 Stated
 Rates       5.56%   6.39%   7.91%    6.50%    5.77%    7.01%             --
-------------------------------------------------------------        ---------

         The  stated  rates of  interest  expressed  in the above  table may not
approximate the actual yield of the securities which the Company currently holds
since the Company has purchased some of its marketable  securities at other than
face value. Additionally,  some of the securities represented in the above table
may be called or redeemed,  at the option of the issuer, prior to their expected
due dates.  If such early  redemptions  occur,  the  Company  may  reinvest  the
proceeds  realized on such calls or  redemptions in marketable  securities  with
stated rates of interest or yields that are lower than those of current holdings
affecting both future cash interest streams and future earnings.

         In addition to investments in marketable securities, the Company places
some of its cash in money market  funds in order to keep cash  available to fund
operations  and to hold  cash  pending  investments  in  marketable  securities.
Fluctuations  in short  term  interest  rates  will  affect  the yield on monies
invested in such money market  funds.  Such  fluctuations  can have an impact on
future cash  interest  streams  and future  earnings  of the  Company,  but such
impacts are not expected to be material.

         Management  believes  that  it has  remedied  all  of  its  significant
information  technology  and  non-information  technology  systems  that  may be
affected  by  the  year  2000  issue.  Management  has  made  inquiries  of  its
significant vendors as to their readiness for the year 2000 issue. The Company's
significant  vendors  have  represented  to the  Company  that  there  is a high
probability that the year 2000 issue will not cause a significant  disruption to
the delivery of goods and services

                                        7


<PAGE>



after 1999.  However,  the Company  gives no assurance as to whether or not this
will be the case.  To date the  Company  has spent  less than  $50,000 to remedy
systems  that may have been  affected by the year 2000 issue and does not expect
future  expenses,  if any,  to be  material.  If it turns  out that  some of the
Company's  systems  or  its  vendors'  systems  are  not  year  2000  compliant,
management  believes  the most likely  worst case  scenario  would be  temporary
reduction in the current level of productivity.  The Company's  contingency plan
includes, but may not be limited to, manual workarounds and a temporary increase
in the current staffing level.

         The Company does not believe that  inflation has had a material  impact
on its results of operations.

Liquidity and Capital Resources

         At June 30, 1999 and December  31, 1998,  cash,  cash  equivalents  and
marketable securities aggregated $49,078,000 and $56,378,000, respectively. This
decrease  was a  result  of the  utilization  of  these  resources  to fund  the
Company's operations.

         To date, the Company has met its cash requirements  through the sale of
its stock, through contract and license revenue, through SBIR grants and through
interest  income  and  gains  resulting  from its  investments.  If the  current
biotechnology  financing  environment  remains  unfavorable,  raising additional
capital may be difficult.

         At June 30, 1999,  the Company had invested an aggregate of $11,273,000
in property and equipment.

         The Company leases  laboratory and office facilities under an agreement
expiring on December 31, 2015.  The minimum  annual  payment  under the lease is
currently $1,530,000.  The lease provides for fixed escalations in rent payments
in the years 2005 and 2010.

         At June 30, 1999, the Company had $49,078,000 in cash, cash equivalents
and marketable securities.  The Company currently intends to utilize these funds
primarily  to  conduct  certain of its  research  programs,  for patent  related
expenditures,  for general corporate purposes, to make leasehold improvements to
its facilities and to purchase  property and equipment.  The Company  expects to
continue to incur operating  losses for a number of years.  The Company believes
that its cash on hand and cash  that it  expects  to  receive  through  interest
payments on its investments,  will be sufficient to fund its operations, as well
as the  Company's  share of  certain  development  costs  under  the  Grunenthal
Agreement, through the year 2001.

         This Report on Form 10-Q contains "forward looking  statements"  within
the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the
Securities  Exchange Act of 1934. Such statements  include,  but are not limited
to, those relating to future cash and spending plans, amounts of future research
funding,  and any other statements  regarding future growth,  future cash needs,
future  operations,   business  plans  and  financial  results,  and  any  other
statements which are not historical facts. When used in this document, the words
"expects," "may,"  "believes," and similar  expressions are intended to be among
the words that identify  forward-looking  statements.  Such  statements  involve
risks  and  uncertainties,  including,  but not  limited  to,  those  risks  and
uncertainties  detailed  in the  Company's  Annual  Report  on Form 10-K for the
fiscal year ended December 31, 1998 (the "1998 Form 10-K"),  including in Item 1
of the 1998 Form 10-K under the captions  "Patents,  Proprietary  Technology and
Trade  Secrets,"  "Competition"  and  "Government  Regulation" as well as in the
section entitled  "Disclosure  Regarding  Forward-Looking  Statements" under the
captions  "Early  Stage  of  Product  Development;  Technological  Uncertainty,"
"Dependence on Collaborative Partners and Licensees for Development,  Regulatory
Approvals,  Manufacturing,  Marketing and Other  Resources"  and  "Uncertainties
Related to Clinical Trials" or detailed from time to time in filings the Company
makes with the SEC. Should one

                                        8


<PAGE>



or more of these  risks  or  uncertainties  materialize,  or  should  underlying
assumptions  prove  incorrect,  actual  outcomes may vary  materially from those
indicated.  Although the Company believes that the expectations reflected in the
forward-looking  statements  contained  herein  are  reasonable,  it can give no
assurance that such expectations will prove to be correct. The Company expressly
disclaims any obligation or undertaking to disseminate  any updates or revisions
to any  forward-looking  statement contained herein to reflect any change in the
Company's  expectations with regard thereto or any change in events,  conditions
or circumstances on which any such statement is based.























































                                        9


<PAGE>



Item 3. Quantitative and Qualitative Disclosures About Market Risk


         Quantitative  and  qualitative  disclosures  about  market  risk (i.e.,
interest rate risk) are included in Item 2 of this Report.



























































                                       10


<PAGE>



                           PART II. OTHER INFORMATION


Item 4.  Submission of Matters to a Vote of Security Holders


         On May 6, 1999, the Company held its annual meeting of stockholders for
the following  purposes:  (i) to elect three Class III directors to the Board of
Directors  (Proposal No. 1); and (ii) to ratify the  appointment by the Board of
Directors  of Ernst & Young LLP as the  independent  auditors of the Company for
the fiscal year ending December 31, 1999 (Proposal No. 2).

         The  stockholders  elected  the  persons  named  below,  the  Company's
nominees for director, as Class III directors of the Company,  casting votes for
such nominees or withholding votes as indicated:

                                    VOTES FOR                VOTES WITHHELD

Zola P. Horovitz                    8,429,329                    28,676
Patrick J. McDonald                 8,429,629                    28,376
Kathleen P. Mullinix                8,428,504                    29,501



         The stockholders approved Proposal No. 2 as follows:


VOTES FOR         VOTES AGAINST         VOTES ABSTAINED       BROKER NON-VOTES

8,456,880              525                    600                    0


































                                       11


<PAGE>



Item 6.  Exhibits and Reports on Form 8-K


(a) Exhibits

Exhibit
  No.       Description
-------     -----------

27          Financial Data Schedule


(b)         Reports on Form 8-K


On April 16, 1999,  the Company filed a Current  Report on Form 8-K stating that
it had issued a press release  announcing the appointment of a new member to the
Company's board of directors.

On May 17, 1999,  the Company filed a Current Report on Form 8-K stating that it
had issued a press release  announcing the termination of its collaboration with
Warner-Lambert Company in the field of galanin.

On May 23, 1999,  the Company filed a Current  Report on Form 8-K announcing the
expiration of a nonexclusive license under certain of its patents, as well as an
option to obtain a license under certain of its patents,  that it had granted to
Glaxo Group Limited.





































                                       12


<PAGE>


                                 SIGNATURE PAGE


Pursuant to the  requirements of Section 13 or 15(d) of the Securities  Exchange
Act of 1934,  the  registrant  has duly  caused  this report to be signed on its
behalf by the undersigned, thereunto duly authorized.

                              SYNAPTIC PHARMACEUTICAL CORPORATION
                                        (Registrant)



Date: August 6, 1999          By:/s/ Kathleen P. Mullinix
                                 -----------------------------
                              Name:  Kathleen P. Mullinix
                              Title: Chairman, President &
                                      Chief Executive Officer



                             By:/s/ Robert L. Spence
                                 -----------------------------
                             Name:  Robert L. Spence
                             Title: Senior Vice President,
                                      Chief Financial Officer & Treasurer







































                                       13